Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update

Initiated Phase 3 VERIFY study of rusfertide in polycythemia vera, reaffirming rusfertide in PV as the Company's primary point of focusPresented t...

Related Keywords

United States ,Russia ,Ukraine ,American ,Pbruce Sands ,Jami Taylor ,Joshuar Mansbach ,Ronald Hoffman ,Kevin Murphy ,Dineshv Patel ,Exchange Commission ,Center Study To Evaluate The Safety ,Development Rd Expenses ,Icahn School Of Medicine At Mount Sinai ,Drug Administration ,Protagonist Therapeutics Inc ,Initiated Phase ,Chief Executive Officer ,Digestive Disease Week ,Subcutaneous Injectable Hepcidin Mimetic ,Polycythemia Vera ,Annual Meeting ,American Society ,Clinical Oncology ,Breakthrough Therapy Designation ,Liver Meeting ,American Association ,Ulcerative Colitis ,Multi Center Study ,Peptide Antagonist ,Severe Ulcerative Colitis ,Icahn School ,Cash Equivalents ,Marketable Securities ,Collaboration Revenue ,Janssen Frontier ,Private Securities Litigation Reform Act ,Consolidated Statements ,Months Ended ,